Cardiff Oncology (CRDF) Stock Forecast & Price Target

Cardiff Oncology is viewed favorably because its lead asset, onvansertib, targets PLK1, a validated oncology mechanism, and has already shown meaningful clinical activity in a large, underserved RAS-mutated metastatic colorectal cancer population. The ongoing CRDF-004 trial reported an ORR of 72.2% with 30mg onvansertib plus FOLFIRI and bevacizumab versus 42.1% in control, while median PFS was not reached versus about 11 months, supporting the drug’s differentiated efficacy and manageable safety profile. The settlement with Nerviano also removes litigation over global rights, strengthens exclusivity and governance around development, and reduces strategic uncertainty as the program advances toward its Phase 3 path.

Cardiff Oncology is facing a material strategic and legal overhang after Nerviano Medical Sciences terminated the onvansertib license agreement, alleging Cardiff breached the contract by failing to address inventorship issues and by not using commercially reasonable efforts to advance development and regulatory approvals. The dispute is especially damaging because Nerviano has also sought transfer of regulatory communications, development data, and trial oversight, creating uncertainty around control of the company’s main clinical asset and threatening continuity of its Phase 2 mCRC program. With the termination first flagged on April 20, 2026 and reiterated on May 27, 2026, the combination of litigation risk, partnership instability, and dependence on a single lead asset supports a negative fundamental outlook.